Strong sales and new head at Roche Diagnostics
This article was originally published in Clinica
Executive Summary
Roche Diagnostics has had another good year in 1999 while announcing its third head of division in as many years. The company saw sales increase by 12% in constant currencies to SwFr5,282 million ($3,545 million) in the year ended December 1999. Current head, Otto Meile, is to retire. He will be replaced by Heino von Prondzynski, who joins from Chiron.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.